(Press-News.org) HOUSTON ― According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.
Findings from the Phase II clinical trial, published today in The Lancet Haematology, represent an important step forward for patients with advanced-phase CML, who tend to have poor outcomes. Limited data on a standard-of-care approach to treating the disease, highlights the need for investigations into additional therapeutics.
“Over the last decade, there have been very few studies that evaluated a regimen to treat this rare disease and identify a potential standard-of-care treatment,” said principal investigator Nicholas Short, M.D., associate professor of Leukemia. “It is important that we get these patients into a state of marrow remission as this will allow them to be considered for a stem cell transplant. We were able to achieve this response in 80% of patients on this trial.”
A total of 20 patients were enrolled in the trial, with 14 having myeloid blast-phase CML, four with accelerated-phase CML, and two with Philadelphia chromosome-positive AML. Overall, 50% of patients achieved a complete remission or complete remission with an incomplete hematological recovery, and an additional 30% of patients achieved a morphologic leukemia-free state. Responses were seen even in patients who had received multiple prior therapies and in those with high-risk cytogenetic or molecular features.
“For this trial, we were able to build on previous preclinical and clinical research conducted at MD Anderson, which identified synergy between the BCL-2 inhibitor, venetoclax and the BCR::ABL1 tyrosine kinase inhibitor, ponatinib,” Short said. “This knowledge led us to consider this novel treatment regimen for this aggressive disease.”
The researchers observed expected side effects, which were consistent with previous studies with the drugs. Common side effects included neutropenia, rash and nausea.
The trial is ongoing and enrolling additional patients. MD Anderson researchers also are conducting additional studies building on the approach of adding targeted therapies into new combinations for patients with advanced-phase CML.
The trial was funded by Takeda Oncology, the National Institutes of Health and the National Cancer Institute Cancer Center Support Grant (P30 CA016672). A complete list of collaborating authors and their disclosures can be found here.
END
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukemia
Eighty percent of patients achieved complete remission when treated with decitabine, venetoclax and ponatinib in Phase II trial
2024-09-17
ELSE PRESS RELEASES FROM THIS DATE:
‘Scuba-diving’ lizards use bubble to breathe underwater and avoid predators
2024-09-17
BINGHAMTON, N.Y. -- Presenting the world’s smallest (and scrappiest) scuba diver: A species of semi-aquatic lizard produces a special bubble over its nostrils to breathe underwater and avoid predators, according to new research from Binghamton University, State University of New York.
Lindsey Swerk, an assistant research professor of biological sciences at Binghamton University, studies water anoles, a type of semi-aquatic lizard found in the tropical forests of southern Costa Rica. She had previously documented the lizards using a bubble underwater. When these lizards feel threatened by a predator, ...
USC launches large-scale nationwide study of type 1 diabetes and brain development
2024-09-17
About half of adults with type 1 diabetes face significant cognitive impairment, including problems with working memory and executive function that affect day-to-day thinking. But less is known about how the condition affects children during a window of time known to be critical for healthy brain development.
A new large-scale longitudinal study, led by the Keck School of Medicine of USC, will unite 12 research centers across the United States to explore that important question. Researchers will collaborate to recruit a large, diverse group of children newly diagnosed with diabetes, taking a sweeping look at the environmental, lifestyle, ...
Ancestry-specific genetic variants linked to multiple sclerosis risk, new study shows
2024-09-17
A landmark study has uncovered novel ancestry-specific genetic variants linked to multiple sclerosis (MS), offering new insights that could reshape treatment approaches for diverse populations affected by the disease.1 The research, presented today at ECTRIMS 2024, is the result of efforts by the Alliance for Research in Hispanic MS (ARHMS) Consortium and is the first large-scale study to identify ancestry-specific genetic effects for MS risk.
In a comprehensive analysis of over 7,000 individuals from self-reported Hispanic (n=4,313; 2,201 MS, 2,112 controls) and African American (n=3,085; 1,584 MS, 1,501 controls) backgrounds, researchers discovered ...
Early high-efficacy treatment significantly reduces long-term disability in children with multiple sclerosis, new study finds
2024-09-17
New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term disability in multiple sclerosis (MS) patients.1
The study, which utilised data from the French MS Registry, Italian MS Register, and the global MSBase Registry, analysed the outcomes of 282 patients with paediatric-onset MS who began experiencing symptoms before the age of 18 years. Patients were divided into two groups based on when they initiated monoclonal antibody treatment: either ...
Terasaki Institute CEO Dr. Ali Khademhosseini awarded the AIChE’s 2024 Andreas Acrivos Professional Progress
2024-09-17
Dr. Ali Khademhosseini, Ph.D., CEO and Director of the Terasaki Institute for Biomedical Innovation (TIBI), is honored with the 2024 Andreas Acrivos Award for Professional Progress in Chemical Engineering by the American Institute of Chemical Engineers (AIChE). This distinguished honor recognizes outstanding progress in the field of chemical engineering.
Named after Dr. Andreas Acrivos, Albert Einstein Professor of Science and Engineering, emeritus at the City College of New York, whose pioneering work in fluid ...
Slow-moving landslides a growing, but ignored, threat to mountain communities
2024-09-17
American Geophysical Union
17 September 2024
AGU Release 24-33
For Immediate Release
This press release is available online at: https://news.agu.org/press-release/slow-landslides-growing-threat-mountain-communities/
Slow-moving landslides a growing, but ignored, threat to mountain communities
Urban growth, climate change, and flood risk at lower elevations can push people to live on steeper, more dangerous terrain
AGU press contact:
Rebecca Dzombak, news@agu.org (UTC-4 hours)
Potsdam press contact:
Stefanie Mikulla, University of Potsdam, presse@uni-potsdam.de (UTC+2 hours)
Researcher contact:
Joaquin Vicente Ferrer, ...
Study finds thousands of browser extensions compromise user data
2024-09-17
Browser extensions, the software add-ons that help users customize and enhance their web browsers, are wildly popular. Some of the most-used extensions find shopping deals, fix grammar and typos, manage passwords, or translate web pages. The types of extensions available are nearly endless, and many have become indispensable tools for businesses and everyday users.
While these extensions can make web browsing more accessible, productive, and rewarding, they are not without risk. New research from Georgia Tech reveals that thousands of browser extensions pose significant threats to privacy, and hundreds automatically ...
Building better DNA editors: Retrons raise the bar for gene research
2024-09-17
SAN FRANCISCO—Within bacterial cells, specialized immune systems known as retrons fend off viral attacks. But that’s not all they can do.
Scientists, including Seth Shipman, PhD, at Gladstone Institutes, have shown that retrons also serve an important purpose in the lab: precise DNA editing. In fact, retrons can be combined with CRISPR—the far more famous bacterial-defense-system-turned-gene-editor—to better edit human cells.
Yet, for all their potential to help scientists better understand disease and develop new therapies, only a small number of retrons have been studied. In nature, many thousands of variations exist, some with greater gene-editing powers than ...
Study shows SIM models improve health data
2024-09-17
First-of-its-kind research by Tarang Parekh, assistant professor of epidemiology, reviewed the State Innovation Models (SIM), a payment system introduced by the Centers for Medicare and Medicaid Services in 2013, which provides financial incentives to states to develop innovative payment models to improve healthcare systems.
In the study, recently published in the American Journal of Epidemiology, Parekh compared data from 2010 to 2015 from three SIM participating states, Arkansas, Massachusetts and Vermont, to Florida, Nebraska and New Mexico, which do not participate in ...
Study suggests humor could help people engage with colorectal cancer information
2024-09-17
BUFFALO, N.Y. – Colorectal cancer (CRC) is no laughing matter. It’s the second-leading cause of cancer deaths globally, according to the World Health Organization. But new research led by the University at Buffalo suggests that humor can be an effective mechanism for reaching people who otherwise avoid information about colorectal cancer screening or other health messaging.
The research, published online ahead of print in the British Journal of Health Psychology, found that in people who demonstrated a ...
LAST 30 PRESS RELEASES:
CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury
Melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1
Single-cell RNA sequencing reveals Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the TMEM131–TNF signaling pathway-mediated differentiation of immunosuppressive dendritic ce
Acta Pharmaceutica Sinica B Volume 15, Issue 7 Publishes
New research expands laser technology
Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain
A high clinically translatable strategy to anti-aging using hyaluronic acid and silk fibroin co-crosslinked hydrogels as dermal regenerative fillers
Mount Sinai researchers uncover differences in how males and females change their mind when reflecting on past mistakes
CTE and normal aging are difficult to distinguish, new study finds
Molecular arms race: How the genome defends itself against internal enemies
Tiny chip speeds up antibody mapping for faster vaccine design
KTU experts reveal why cultural heritage is important for community unity
More misfolded proteins than previously known may contribute to Alzheimer’s and dementia
“Too much going on”: Autistic adults overwhelmed by non-verbal social cues
What’s driving America’s deep freezes in a warming world?
A key role of brain protein in learning and memory is deciphered by scientists
Heart attacks don’t follow a Hollywood script
Erin M. Schuman wins 2026 Nakasone Award for discovery on neural synapse function and change during formation of memories
Global ocean analysis could replace costly in-situ sound speed profiles in seafloor positioning, study finds
Power in numbers: Small group professional coaching reduces rates of physician burnout by nearly 30%
Carbon capture, utilization, and storage: A comprehensive review of CCUS-EOR
New high-temperature stable dispersed particle gel for enhanced profile control in CCUS applications
State gun laws and firearm-related homicides and suicides
Use of tobacco and cannabis following state-level cannabis legalization
Long-term obesity and biological aging in young adults
Eindhoven University of Technology and JMIR Publications announce unlimited open access publishing agreement
Orphan nuclear receptors in metabolic dysfunction-associated steatotic liver disease development
A technological breakthrough for ultra-fast and greener AI
Pusan National University researchers identify key barriers hindering data-driven smart manufacturing adoption
Inking heterometallic nanosheets: A scalable breakthrough for coating, electronics, and electrocatalyst applications
[Press-News.org] Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukemiaEighty percent of patients achieved complete remission when treated with decitabine, venetoclax and ponatinib in Phase II trial